Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

医学 阿西替尼 舒尼替尼 肾细胞癌 彭布罗利珠单抗 内科学 中期分析 临床终点 肿瘤科 人口 肾癌 临床试验 癌症 免疫疗法 环境卫生
作者
Thomas Powles,Elizabeth R. Plimack,Denis Soulières,Tom Waddell,V.P. Stus,Rustem Gafanov,Dmitry Nosov,Frédéric Pouliot,Bohuslav Melichar,Ihor Vynnychenko,Sérgio Jobim Azevedo,Delphine Borchiellini,Raymond S McDermott,Jens Bedke,Satoshi Tamada,Lina Yin,Mei Chen,L. Rhoda Molife,Michael B. Atkins,Brian I. Rini
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (12): 1563-1573 被引量:759
标识
DOI:10.1016/s1470-2045(20)30436-8
摘要

Background The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma. Methods In the ongoing, randomised, open-label, phase 3 KEYNOTE-426 study, adults (≥18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospitals and cancer centres) across 16 countries. Patients were randomly assigned (1:1) to receive 200 mg pembrolizumab intravenously every 3 weeks for up to 35 cycles plus 5 mg axitinib orally twice daily or 50 mg sunitinib monotherapy orally once daily for 4 weeks per 6-week cycle. Randomisation was done using an interactive voice response system or integrated web response system, and was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographical region. Primary endpoints were overall survival and progression-free survival in the intention-to-treat population. Since the primary endpoints were met at the first interim analysis, updated data are reported with nominal p values. This study is registered with ClinicalTrials.gov, NCT02853331. Findings Between Oct 24, 2016, and Jan 24, 2018, 861 patients were randomly assigned to receive pembrolizumab plus axitinib (n=432) or sunitinib monotherapy (n=429). With a median follow-up of 30·6 months (IQR 27·2–34·2), continued clinical benefit was observed with pembrolizumab plus axitinib over sunitinib in terms of overall survival (median not reached with pembrolizumab and axitinib vs 35·7 months [95% CI 33·3–not reached] with sunitinib); hazard ratio [HR] 0·68 [95% CI 0·55–0·85], p=0·0003) and progression-free survival (median 15·4 months [12·7–18·9] vs 11·1 months [9·1–12·5]; 0·71 [0·60–0·84], p<0·0001). The most frequent (≥10% patients in either group) treatment-related grade 3 or worse adverse events were hypertension (95 [22%] of 429 patients in the pembrolizumab plus axitinib group vs 84 [20%] of 425 patients in the sunitinib group), alanine aminotransferase increase (54 [13%] vs 11 [3%]), and diarrhoea (46 [11%] vs 23 [5%]). No new treatment-related deaths were reported since the first interim analysis. Interpretation With extended study follow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior clinical outcomes over sunitinib. These results continue to support the first-line treatment with pembrolizumab plus axitinib as the standard of care of advanced renal cell carcinoma. Funding Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘先生发布了新的文献求助10
刚刚
刚刚
暖若安阳完成签到,获得积分10
刚刚
zhang完成签到,获得积分10
刚刚
K03完成签到 ,获得积分10
1秒前
雪白雍完成签到,获得积分10
1秒前
隐形采萱发布了新的文献求助10
1秒前
1秒前
七里香完成签到,获得积分10
2秒前
美好的易文完成签到 ,获得积分10
2秒前
tt发布了新的文献求助10
2秒前
西科Jeremy完成签到,获得积分10
2秒前
初醒完成签到,获得积分10
3秒前
Anna-crystal完成签到,获得积分10
3秒前
懵懂的曼寒完成签到,获得积分10
3秒前
suky发布了新的文献求助10
3秒前
肖女士完成签到,获得积分10
3秒前
七七完成签到 ,获得积分10
4秒前
hoijuon发布了新的文献求助10
4秒前
榛糕李完成签到,获得积分10
4秒前
FashionBoy的应助被研友_89NQqL采纳,获得10
4秒前
迷路大白完成签到,获得积分10
4秒前
dildil完成签到,获得积分10
4秒前
北天辰发布了新的文献求助10
4秒前
5秒前
5秒前
心理之路修远兮完成签到,获得积分10
5秒前
奇点完成签到,获得积分10
6秒前
111发布了新的文献求助10
6秒前
云中雾完成签到,获得积分10
6秒前
华清如发布了新的文献求助10
6秒前
6秒前
liangchao发布了新的文献求助10
7秒前
Elaine完成签到,获得积分10
7秒前
rudjs完成签到,获得积分10
7秒前
ding的应助被qianlan采纳,获得10
7秒前
醉熏的西牛完成签到 ,获得积分10
7秒前
被风吹过的路的应助被gjy采纳,获得10
8秒前
蔚岚影落完成签到,获得积分10
8秒前
傻芙芙的完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042